JNK2 promotes cJun activation

Credit: Courtesy of Kevan Shokat" /> Credit: Courtesy of Kevan Shokat Applying chemical genetics to mice, Roger Davis at University of Massachusetts Medical School and the Howard Hughes Medical Institute, and colleagues found that JNK2 promotes phosphorylation and activation of cJun.1 "It is an elegant and solid paper that illustrates the power of chemical genetics and it settles a controversy in the field," says Faculty of 1000 member Filippo Giancotti of Memorial Sloan-Kettering Ca

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Applying chemical genetics to mice, Roger Davis at University of Massachusetts Medical School and the Howard Hughes Medical Institute, and colleagues found that JNK2 promotes phosphorylation and activation of cJun.1 "It is an elegant and solid paper that illustrates the power of chemical genetics and it settles a controversy in the field," says Faculty of 1000 member Filippo Giancotti of Memorial Sloan-Kettering Cancer Center in New York.

"Based on the knockout approach, it had been concluded that JNK2 is a negative regulator of cJun and cell proliferation whereas JNK1 promotes this process. [This contradicts] observations that both kinases phosphorylate the same sites in cJun. By introducing in mice a mutant form of JNK2 [that is] exquisitely sensitive to an otherwise inactive kinase inhibitor, the authors demonstrated that JNK2 promotes phosphorylation of cJun and cell proliferation.

This is a particularly vivid illustration that the interpretation of genetic experiments using traditional knockout ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies